Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Toripalimab plus chemotherapy also reduced the risk of disease progression or death by 48% and the risk of death by 37%, all while demonstrating a manageable safety profile.
- Toripalimab plus chemotherapy also reduced the risk of disease progression or death by 48% and the risk of death by 37%, all while demonstrating a manageable safety profile.
- So far, toripalimab has been approved for marketing in the Chinese mainland and the US.
- Several NDAs are currently under regulatory review in the European Union, UK, Australia, Singapore, Malaysia and Hong Kong Special Administrative Region (“SAR”).
- Furthermore, NDAs for toripalimab have also been submitted in India, South Africa, Chile and Jordan.